[go: up one dir, main page]

WO2009035627A2 - Système et procédé pour suivre un changement tissulaire pendant un traitement hifu - Google Patents

Système et procédé pour suivre un changement tissulaire pendant un traitement hifu Download PDF

Info

Publication number
WO2009035627A2
WO2009035627A2 PCT/US2008/010605 US2008010605W WO2009035627A2 WO 2009035627 A2 WO2009035627 A2 WO 2009035627A2 US 2008010605 W US2008010605 W US 2008010605W WO 2009035627 A2 WO2009035627 A2 WO 2009035627A2
Authority
WO
WIPO (PCT)
Prior art keywords
image
treatment
region
interest
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/010605
Other languages
English (en)
Other versions
WO2009035627A3 (fr
Inventor
Wo-Hsing Chen
Roy Carlson
Clint S. Weis
Ralf Seip
Narendra T. Sanghvi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Focus Surgery Inc
Original Assignee
Focus Surgery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Focus Surgery Inc filed Critical Focus Surgery Inc
Priority to CA2699408A priority Critical patent/CA2699408C/fr
Priority to ES08830580T priority patent/ES2424874T3/es
Priority to EP08830580.0A priority patent/EP2207596B1/fr
Priority to JP2010524860A priority patent/JP5462167B2/ja
Publication of WO2009035627A2 publication Critical patent/WO2009035627A2/fr
Publication of WO2009035627A3 publication Critical patent/WO2009035627A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A61N7/02—Localised ultrasound hyperthermia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/36—Image-producing devices or illumination devices not otherwise provided for
    • A61B90/37—Surgical systems with images on a monitor during operation
    • A61B2090/378—Surgical systems with images on a monitor during operation using ultrasound

Definitions

  • the present invention relates to an apparatus and related methods for the treatment of tissue, and in particular, for the non-invasive treatment of diseased tissue.
  • HIFU high intensity focused ultrasound
  • the techniques, methods, and apparatus discussed herein have applicability to the treatment of tissue in general, this discussion will focus primarily on the treatment of prostate tissue including Benign Prostatic Hyperplasia (BPH) and prostatic cancer.
  • BPH Benign Prostatic Hyperplasia
  • the disclosed apparatus and methods will find applications in localization and treatment of a wide range of diseases which manifest themselves in a localized or "focal" manner, including cancers of the breast, brain, liver, and kidney.
  • the disclosed apparatus uses an intracavity probe which will be particularly useful for focal diseases which are accessible to a transesophageal, laparoscopic or transvaginal probe.
  • a transvaginal probe according to the present invention will provide a minimally invasive sterilization procedure on an outpatient basis, as well as therapy for fibroids, and endometrial ablation. Additionally, in the case of a transducer with multiple focal lengths, blood vessels may be selectively targeted to effect coagulation and cauterization of internal bleeding.
  • HIFU Therapy is defined as the provision of high intensity focused ultrasound to a portion of tissue at or proximate to a focus of a transducer. It should be understood that the transducer may have multiple foci and that HIFU Therapy is not limited to a single focus transducer, a single transducer type, or a single ultrasound frequency.
  • HIFU Treatment is defined as the collection of one or more HIFU Therapies. A HJFU Treatment may be all of the HIFU Therapies administered or to be administered, or it may be a subset of the HIF 1 U Therapies administered or to be administered.
  • HIFU System is defined as a system that is at least capable of providing a HIFU Therapy.
  • an apparatus for treating tissue in a treatment region comprising a transducer which is positionable proximate to the tissue and a positioning member coupled to the transducer and configured to position the transducer.
  • the transducer being configured to emit ultrasound energy and to receive ultrasound energy.
  • the apparatus further comprising a controller operably coupled to the transducer and to the positioning member. The controller being configured to position the transducer with the positioning member and to operate the transducer in an imaging mode wherein images of the tissue in the treatment region are obtained from ultrasound energy sensed by the transducer and in a therapy mode wherein a plurality of treatment sites are treated with a HIFU Therapy with the transducer.
  • the controller being further configured to monitor a plurality of regions of interest in the treatment region and to determine a tissue change value for each region of interest based on a frequency analysis of at least two images of the plurality of images. Each region of interest corresponding to a multi-dimensional portion in each of the at least two images.
  • an apparatus for treating tissue in a treatment region comprising a transducer which is positionable proximate to the tissue, the transducer being configured to emit ultrasound energy and to receive ultrasound energy; a positioning member coupled to the transducer and configured to position the transducer; and a controller operably coupled to the transducer and to the positioning member.
  • the controller including means for determining a tissue change value for a region of interest in the treatment region.
  • a method of providing treatment to a treatment region of tissue comprising the steps of acquiring a first image including a treatment site prior to a direct treatment with a HIFU Therapy, performing the direct treatment of the treatment site with the HlFU Therapy, acquiring a second image including the treatment site subsequent to the direct treatment, and determining a tissue change value in a region of interest of the tissue based on a first power spectrum of a portion of the first image corresponding to the region of interest and a second power spectrum of a portion of the second image corresponding to the region of interest.
  • the first image being a multi-dimensional image.
  • the second image being a multidimensional image.
  • the region of interest including the treatment site.
  • a method of providing treatment to a treatment region of tissue comprising the steps of: monitoring a level of a tissue change in a region of interest of the treatment region due to an indirect heating of the tissue in the region of interest in response to a direct treatment of at least one treatment sites with the HIFU Therapy in the treatment region outside of the region of interest and determining whether to provide a direct treatment with the HIFU Therapy to a treatment site within the region of interest based on the level of the tissue change.
  • the level of the tissue change being determined by a comparison of the power spectra of at least two images including the region of interest.
  • a method of providing treatment to a treatment region of tissue comprising the steps of: performing acquiring a first image including a treatment site prior to a direct treatment with a HIFU Therapy, the first image being a multi-dimensional image; performing the direct treatment of the treatment site with the HIFU Therapy; acquiring a second image including the treatment site subsequent to the direct treatment, the second image being a multi-dimensional image; determining an indication of a tissue change in a region of interest of the tissue from a frequency domain analysis of the first image and the second image; and providing a color-coded visual indicator on an image of the treatment region.
  • the color-coded visual indicator providing an indication of a degree of tissue change.
  • FIG. 1 is schematic view of an exemplary HIFU System of the present invention, the HIFU System being capable of imaging the tissue of the patient and to provide HIFU Therapy to at least a portion of the tissue at or proximate to a focus of a transducer of the HIFU System;
  • Fig. 2 is an exemplary embodiment of the HIFU System of Fig. 1;
  • Fig. 3 is an exemplary method for treating tissue
  • Fig. 4 is an exemplary method for treating tissue
  • FIG. 5 represents exemplary sagittal image planes
  • Fig. 6 represents exemplary echo signals received for a given sagittal image plane
  • Fig. 7 represents a first exemplary method for the acquisition of 2D RF
  • Fig. 8 represents a second exemplary method for the acquisition of 2D
  • Fig. 9 represents exemplary frequency bands of an exemplary power spectrum
  • Fig. 10 is an exemplary method for determining a tissue change value
  • Fig. 11 is an exemplary method for determining if an additional treatment is to be performed at a given treatment site
  • Fig. 12 is an exemplary method to determine the parameters for a current treatment site based on the tissue change at a prior treatment site;
  • Fig. 13 is an exemplary method to determine whether a given treatment site has been sufficiently treated by indirect treatment
  • Fig. 14 is an exemplary screen shot of the display of the HIFU System of Fig. 1 illustrating inputs for modifying the gain parameters during a diagnostic mode of operation;
  • Fig. 15 is an exemplary screen shot of the display of the HIFU System of Fig. 1 illustrating an image of the prostate including visual indicators of the tissue change and a summary of the TCM;
  • Fig. 16 is a detail view of the summary of Fig. 15.
  • Fig. 17 is an exemplary screen shot of the display of the HIFU System of Fig. 1 illustrating three-dimensional volumetric image including visual indicators of the tissue change.
  • FIG. 1 An exemplary HIFU System 100 is shown in Fig. 1.
  • Probe 102 is operably connected to controller 108 through positioning member 106. However, as indicated by line 105 probe 102 may be directly connected with controller 108.
  • Positioning member 106 is configured to linearly position transducer member 104 along directions 113, 114 and to angularly position transducer member 104 in directions 115, 1 16.
  • Transducer member 104 is positioned generally proximate to a region of tissue 10. In the case of the prostate, transducer 104 is positioned generally proximate to the prostate by the transrectal insertion of probe 102. Transducer member 104 is moved by positioning member 106 and controlled by controller 108 to provide imaging of at least a portion of tissue 10 including at least one treatment region 12 and to provide HIFU Therapy to portions of the tissue within at least one treatment region 12. As such, HIFU System 100 may operate in an imaging mode wherein at least a portion of tissue 10 may be imaged and in a therapy mode wherein HIFU Therapy is provided to portions of tissue 10 within at least one treatment region. As stated herein, treatment region 12 is defined as one or more portions of tissue which are to be treated during a HIFU Treatment. Treatment region 12 is illustratively shown as a continuous region. However, a treatment region might involve two or more distinct regions.
  • transducer member 104 is a single crystal two element transducer.
  • An exemplary transducer is disclosed in U.S. Patent No. 5,117,832, the disclosure of which is expressly incorporated herein by reference.
  • transducer 104 is capable of providing imaging of at least a portion of tissue 10 in an imaging mode and of providing HIFU Therapy to at least a portion of tissue 10 within treatment region 12 in a therapy mode.
  • transducer geometries having a single focus or multiple foci and associated controls may be used including transducers which are phased arrays, such as the transducers disclosed in pending U.S. Patent Application Serial No. 11/070,371, filed March 2, 2005, titled “Ultrasound Phased Arrays," Attorney Docket No. INT-POOl-01, the disclosure of which is expressly incorporated herein by reference. Additional exemplary transducers and associated controls are disclosed in U.S. Patent No. 5,762,066; U.S. Abandoned Patent Application Serial No. 07/840,502 filed February 21, 1992; U.S. Patent No.
  • a portion of probe 102 is covered by an acoustic membrane 103.
  • Acoustic membrane 103 is an expandable membrane whose overall size is increased by placing a fluid on an interior of acoustic membrane 103.
  • the fluid is water or a generally acoustic transparent material and is provided by a reservoir or a chiller. The fluid may be used to remove heat from proximate to transducer 104 as well as expanding acoustic membrane 103.
  • acoustic membrane 103 is expanded such that it contacts or generally is adjacent to the surrounding tissue, such as a rectal wall.
  • acoustic membrane 103 is a condom placed over a tip of probe 102, sealed with o-rings, and filled with water.
  • Exemplary acoustic membranes and details of their operation in relation to respective other portions of exemplary HIFU Systems are provided in U.S. Patent No. 5,762,066, U.S. Patent No. 5,993,389, and U.S. Provisional Patent Application Serial No. 60/686,499, filed June 1, 2005, the disclosures each of which are expressly incorporated by reference herein.
  • controller 108 is configured to execute one or more of the methods discussed herein. In one embodiment, at least a portion of each method executed by controller 108 is provided as a portion of software 109. [0035] Referring to Fig. 2, an exemplary HIFU System 200 is shown, the
  • HIFU System 200 includes a console 202 which houses or supports a controller (not shown), such as a processor and associated software; a printer 204 which provides hard copy images of tissue 10 and/or reports; a user input device 206 such as a keyboard, trackball, and/or mouse; and a display 208 for displaying images of tissue 10 and software options to a user, such as a color display. Further, shown is a probe 210 which includes a transducer member (not shown), and a positioning member (not shown). Also shown is an articulated probe arm 212 which is coupled to console 202.
  • a controller not shown
  • printer 204 which provides hard copy images of tissue 10 and/or reports
  • a user input device 206 such as a keyboard, trackball, and/or mouse
  • a display 208 for displaying images of tissue 10 and software options to a user, such as a color display.
  • a probe 210 which includes a transducer member (not shown), and a positioning member (not shown).
  • Articulated probe arm 212 orients and supports probe 210.
  • a chiller 214 is also shown. Chiller 214, in one embodiment, provides a water bath with a heat exchanger for the transducer member of probe 210 to actively remove heat from the transducer member during a HIFU Treatment.
  • Patent No. 5,443,069 U.S. Patent No. 5,470,350, U.S. Patent No. 5,492,126; U.S. Patent No. 5,573,497, U.S. Patent No. 5,601,526; U.S. Patent No. 5,620,479 ; U.S. Patent No. 5,630,837; U.S. Patent No. 5,643,179; U.S. Patent No. 5,676,692; U.S. Patent No. 5,840,031 ; U.S. Patent No. 5,762,066; U.S. Patent No. 6,685,640; U.S. Patent Application Serial No. 1 1/070,371, filed March 2, 2005, titled "Ultrasound Phased Arrays," Attorney Docket No.
  • HIFU System 100 provides HIFU Therapy to tissue 10.
  • the characteristics of the tissue 10 changes due to the HIFU Therapy.
  • Some HIFU- induced lesions in tissue 10 are visually detectable changes through standard 2-D ultrasound (echo) imaging techniques (i.e. the HIFU-induced tissue change is sufficiently large enough to create a noticeable difference between a BEFORE and an AFTER HIFU image that the operator can see).
  • the application of HIFU may result in successful treatment of the tissue, even though these changes are not visually detectable through standard 2-D ultrasound (echo) imaging (i.e. cases wherein the tissue change due to HIFU is small or subtle enough so that it does not cause a noticeable change in standard ultrasound images).
  • TCM tissue change monitoring methods
  • TCM uses the same 2-D ultrasound echo data which is used for traditional ultrasound imaging.
  • traditional ultrasound imaging this ultrasound echo data is rectified, envelope-detected, log-scaled, and then mapped to a grayscale table for displaying on the screen.
  • This processing removes the phase information from the ultrasound back scattered data and presents images based on intensity (square of pressure) values of the backscattered radio frequency signals.
  • TCM uses the phase information and the amplitude information of the ultrasound data to determine the changes introduced to the tissue due to exposure to HIFU Therapy.
  • the treatment region and surrounding tissue is imaged with HIFU System 100 using conventional ultrasound techniques.
  • HIFU System 100 generates and stores a plurality of 2-D images of tissue 10 including treatment region 12.
  • HIFU System 100 generates and stores a plurality of transverse or sector images about every 3 mm along the treatment region, such as image 121 in Fig. 15, and generates and stores a plurality of sagittal (or linear) images about every 3° (as represented by image planes 250 in Fig. 5), such as image 123 in Fig. 15.
  • the sagittal images are comprised of a plurality of one- dimensional radio frequency echoes 252 (see Fig.
  • each one-dimensional radio frequency echoes are included in the sagittal image with each one-dimensional radio frequency echo being spaced about 0.2 millimeters from adjacent one-dimensional radio frequency echoes.
  • Each one-dimensional radio frequency echo is acquired at a corresponding transducer position along the x-axis 114. In other examples, different spacing of the transverse and sagittal images are used.
  • treatment region is defined as one or more portions of tissue which are to be treated during a HIFU Treatment.
  • treatment region is used to describe the overall area being treated during a HIFU Treatment.
  • treatment region may also be used to describe one or more sub- regions of the overall area being treated, such as one or more treatment segment(s) and/or one or more treatment site(s).
  • TCM provides a method for detecting changes in the tissue being treated with HIFU Therapy even if the HIFU Therapy does not result in large lesions that produce very large backscattered signals.
  • TCM is the process of acquiring ultrasound backscattered RF echo data prior to, during, and/or after the delivery of HIFU Therapy, processing this data to determine a level of tissue change, assigning a visual indicia to the level of tissue change, and superimposing the visual indicia on an image of the treatment region.
  • Exemplary images include standard 2D ultrasound images (such as images 121 and 123 in Fig. 15) and volumetric ultrasound images, such as image 125 in Fig. 17.
  • Image 125 includes a three-dimensional representation of the backscatter echo data, the visual indicator of the tissue change, and a representation of the position of the transducer 104.
  • FIG. 3 an exemplary embodiment 300 of a TCM is shown.
  • the HIFU System 100 acquires a reference image which includes the region that will be treated by the HIFU Therapy, as represented by block 302. This image is referred to as a BEFORE image.
  • the BEFORE image may be acquired just prior to the application of HIFU Therapy or may be acquired many seconds prior to the application of HIFU Therapy.
  • the BEFORE image is a sagittal image comprised of a plurality of one-dimensional echo signals.
  • a region of interest is identified in the image, as represented by block 304.
  • the ROI is a 2D sub-region which contaias echoes of the tissue volume that will be treated by the HIFU transducer in a subsequent HIFU Treatment.
  • the ROI includes the tissue located in the focal zone of the transducer (such as ROI 260 in Fig. 6).
  • the ROI includes the tissue located in the region between the transducer and the focal zone of the transducer (such as ROI 262 in Fig. 6).
  • the ROI includes the tissue located in the region beyond the focal zone of the transducer (such as ROI 264 in Fig. 6).
  • the ROI includes the tissue located between the transducer and the focal zone of the transducer, located in the focal zone of the transducer, and located in the region beyond the focal zone of the transducer.
  • the ROI is approximately from 10 millimeters to about 15 millimeters in depth and about 3 millimeters wide which corresponds to about 15 adjacent one-dimensional echo lines 252 in Fig. 6.
  • the RF data contained in the ROI is one of the two input data sets used to determine the tissue change value caused by an exposure to HIFU Therapy.
  • the second input data set is the RF data from the ROI acquired subsequent to a HIFU exposure.
  • An image is acquired after the HIFU exposure, as represented by block 306. This is referred to as an AFTER image.
  • the same ROI is identified in the AFTER image, as represented by block 308.
  • a parameter value representative of the tissue change is determined based on the BEFORE image and the AFTER image, as represented by block 310. In one embodiment, this parameter value is a level that is based on the tissue change value.
  • a first BEFORE image is acquired at time T 0 .
  • a first HIFU Therapy is provided between time To and time Ti.
  • a first AFTER image is acquired at time Ti.
  • a parameter value representative of the amount of tissue change during the first HIFU Therapy is determined.
  • the first AFTER image is then used as a second BEFORE image.
  • a second HIFU Therapy is provided between time Ti and time T 2 .
  • a second AFTER image is acquired at time T 2 .
  • a parameter value representative of the amount of tissue change during the second HIFU Therapy is determined.
  • the second AFTER image is then used as a third BEFORE image and the process continues to repeat.
  • FIG. 8 another exemplary timeline for a portion of a HIFU
  • a first BEFORE image is acquired at time T 0 .
  • a first HIFU Therapy is provided between time To and time Ti.
  • a first AFTER image is acquired at time Ti.
  • a parameter value representative of the amount of tissue change during the first HIFU Therapy is determined.
  • a second HDFU Therapy is provided between time Ti and time T 2 .
  • a second AFTER image is acquired at time T 2 .
  • a parameter value representative of the amount of tissue change during the first HIFU Therapy and the second HIFU Therapy is determined.
  • the first AFTER image is then used as a second BEFORE image.
  • a third HIFU Therapy is provided between time T 2 and time T 3 .
  • a third AFTER image is acquired at time T 3 .
  • a parameter value representative of the amount of tissue change during the second HIFU Therapy and the third HIFU Therapy is determined.
  • the second AFTER image is then used as a third BEFORE image and the process continues to repeat.
  • the situation shown in Fig. 8 is beneficial in situations wherein successive treatment sites are in close proximity, such as next to each other.
  • the HIFU Therapy for an n" 1 treatment site may likely cause a tissue change in the adjacent n+1 treatment site due to heat conduction.
  • the image recorded after the exposure of the nth treatment site is used as the BEFORE image of the n+1 treatment then a portion of the tissue change at the n+1 treatment site is not taken into account (the portion corresponding to the nth exposure).
  • the BEFORE image prior to the nth exposure as the BEFORE image for the n+1 exposure the overall tissue change to the n+1 treatment site due to the nth exposure and the n+1 exposure may be determined.
  • the parameter value representative of the level of tissue change is determined.
  • a power spectrum is determined for each of the one dimensional echoes of the ROI for each of the BEFORE image and the AFTER image.
  • two two-dimensional power spectra are known.
  • One corresponding to the BEFORE image ROI and one corresponding to the AFTER image ROI are determined.
  • An average power spectrum for each of the BEFORE image ROI and the AFTER image ROI are determined.
  • two one-dimensional power spectra are known.
  • the energy level of a plurality of frequency bands is determined.
  • three frequency bands 272, 274, and 276 are determined for the averaged power spectrum 270 of the AFTER image.
  • the same frequency bands are used in the averaged power spectrum of the BEFORE image.
  • the energy levels for each of frequency bands 272, 274, and 276 are known.
  • the determined energy level difference between the BEFORE image and the AFTER image is determined for each frequency band.
  • the largest of the determined differences in one embodiment, is the parameter value representative of the level of tissue change between the BEFORE image and the AFTER image.
  • the largest of the determined differences is mapped to a level of tissue change.
  • a visual indicia indicative of the level of tissue change is displayed on the display 112 of HIFU System 100, as represented by block 312.
  • the visual indicia is a color.
  • the following table illustrates an exemplary mapping of the difference value to a visual indicator, a color, for a piece of chicken test tissue having an initial temperature of about 30 to about 35 degrees Celsius (C).
  • the color is overlaid onto a displayed ultrasound image, such as image 123 in Fig. 15, in a region corresponding to the treatment site in the ROI. This process is repeated for each successive BEFORE image and AFTER image.
  • HIFU System 100 performs a diagnostic mode of operation 402 and a treatment mode of operation 404. HIFU System 100 further performs an imaging mode of operation in which images of treatment region 12 are acquired.
  • a two dimensional reference image is acquired as represented by block 406.
  • a pulse is sent into the tissue and the echoes from that pulse are digitized and converted into an image.
  • the time for a given echo is directly proportional to the depth of the echo source.
  • a gain parameter is applied to compensate for this physical phenomenon by generally increasing the gain for deeper tissue echoes.
  • the gain parameter is generally known as either TGC which is an acronym for Time Gain Control or DGC which is an acronym for Depth Gain Control.
  • the image is analyzed to determine if the signal to noise level is sufficient for TCM, as represented by block 408.
  • the RF signals of the ultrasound image which correspond to a region of interest is examined.
  • the mean of the absolute values of the RF signal is determined.
  • the percentage of data points in the RF signal that are saturated is determined. A data point is saturated if its value exceeds or is equal to the maximum value that the analog to digital converter is able to digitize. If the mean value of the RF signal is below a threshold then the gain parameter is increased (as represented by block 409) and another ultrasound image is taken and the RF signal is tested once again. This approach helps prevent false positive readings due to poor signal to noise level from cysts (dark areas) in the tissue.
  • An exemplary mean value threshold is about 10% of maximum digitization value. If the percent of saturated data points is above a threshold, then the gain parameter is decreased and another ultrasound image is taken and the RF signal is tested once again. This approach helps prevent false negative readings from excessively large signals caused by high gain in settings in the ultrasound image (saturation).
  • An exemplary threshold percentage is about 0.1 percent. Assuming that both the mean value and the saturation percentage satisfy their respective thresholds, a HIFU Therapy including tissue change monitoring may be performed. If one or both of the mean value and the saturation percentage do not satisfy their respective thresholds, then a HIFU Therapy may still be performed. TCM may still be on in each HIFU treatment sites except where the mean value does not satisfy the threshold.
  • both a signal to noise level and a RF saturation level are determined and presented with a scale meter 280 (see Fig. 14) on the display 112 of HIFU System 100.
  • the operator may make fine adjustments for a gain parameter with input controls 282A-H in Fig. 14 and a main gain with input control 284 in Fig. 14.
  • the gain parameters corresponding to input controls 282A-H each correspond to a given depth range. As such, the gain for various depths may be adjusted independently.
  • the main gain input 284 adjusts the gain for all depths at the same time.
  • the BEFORE image is a two-dimensional image, such as a sagittal image, that includes the plane of the upcoming HIFU exposure (i.e. a plane containing the focal point of the transducer).
  • the BEFORE image is stored in memory.
  • HIFU Therapy is applied to the tissue as represented by block 412.
  • an AFTER image is acquired for the treatment region, as represented by block 414.
  • the AFTER image like the BEFORE image, in one embodiment is a two-dimensional image that includes the plane in which the HIFU Therapy was directed.
  • the AFTER image is stored in memory.
  • the BEFORE image is examined to determine whether the signal has a sufficient signal to noise ratio to be analyzed for tissue change monitoring, as represented by blocks 416 and 418.
  • the mean of the absolute values of RF data in the treatment region in the BEFORE image is determined. If the mean value is below a threshold, then the BEFORE image is not considered appropriate for analyzing for tissue change monitoring and a tissue change indicator is set to "no data", as represented by block 420.
  • the indicator is a visual indicator on the display of HIFU System 100. If the mean value satisfies the threshold, then the amount of tissue change is determined, as represented by block 422.
  • An exemplary method for determining the amount of tissue change is provided in Fig. 10 discussed herein.
  • a parameter value is determined which provides an indication of the level of tissue change.
  • the parameter is an energy increase.
  • the parameter is mapped to a visual indicator and displayed on display of HIFU System 100, as represented by block 424.
  • the visual indicator is a color and the visual indicator is overlaid on a two-dimensional image of the treatment region and embedded into a three-dimensional volume image.
  • discrete colors are provided which correspond to discrete levels of energy increase.
  • a green color code corresponds to no (or very small) tissue change
  • a yellow color code corresponds to a moderate tissue change
  • an orange corresponds to a large tissue change.
  • an exemplary BEFORE image and an exemplary AFTER image are both in a plane 250 and are acquired by translating transducer in the x-direction 114. At each discrete location in the x- direction 114 a one dimensional echo signal 252 is recorded. An exemplary spacing of the discrete locations is about 0.2 millimeters.
  • a plurality of one-dimensional echo signals 252 are shown in Fig. 6.
  • one-dimensional echo lines 252 are included in each of the BEFORE image an the AFTER image. In one embodiment, about 225 one-dimensional echo lines 252 are included in each of the BEFORE image and the AFTER image.
  • a width of a region of interest is comprised of a discrete number of one-dimensional echo lines 252.
  • An exemplary width is about 15 one-dimensional echo lines 252 at a spacing of about 0.2 millimeters. This width is associated with a first treatment site. The fifteen adjacent one-dimensional echo lines 252 arc associated with a second treatment site, although not necessarily second in time.
  • a first region of interest 260 corresponds to the focal zone. In one example, the first region corresponds to a depth of about 3.5 cm to about 4.5 cm.
  • a second region of interest 262 corresponds to a pre-focal region. In one example, the second region of interest corresponds to a depth of about 2.8 cm to about 3.5 cm.
  • the detection of pre-focal heating may be able to save therapy time by optimizing the radial overlap of consecutive therapy zones.
  • a third region of interest 264 corresponding to the region beyond the focal zone (beyond the first region of interest) is also monitored. Additional regions of interest such as for other treatment sites may also be monitored. [0065] Referring to Fig. 10, the parameter corresponding to the tissue change in a given region of interest is determined.
  • the power spectrum for the region of interest for each of the BEFORE image and the AFTER image is determined, as represented by block 440.
  • the time domain echoes signals for each one-dimensional echo line in the region of interest are converted to the frequency domain for the depth range corresponding to the region of interest for both the BEFORE image and the AFTER image.
  • a discrete Fourier transform is used to convert the respective signals to the frequency domain.
  • the converted signals are then averaged for each of the BEFORE image and the AFTER image to form a single power spectrum for each of the BEFORE image and the AFTER image. It should be noted if multiple regions of interest are being monitored then power spectra for those regions of interest in the BEFORE image and the AFTER image are also determined.
  • An exemplary power spectrum 270 is illustrated in Fig.
  • a plurality of frequency bands 272, 274, 276 are indicated on the power spectrum.
  • the frequency bands correspond to a fundamental frequency band 274, a sub- harmonic frequency band 272, and a harmonic frequency band 276 by way of example.
  • the fundamental frequency band correspond to the bandwidth of about 3 megahertz (MHZ) to about 5 MHz
  • the sub-harmonic frequency band corresponds to a bandwidth of about 1 MHz to about 3 MHz
  • the harmonic frequency band corresponds to the bandwidth of about 6 MHz to about 9 MHz.
  • the change in energy in each of the frequency bands 272, 274, 276 between the BEFORE image and the AFTER image is determined, as represented by block 442.
  • the average power spectrum for each frequency band in both of the BEFORE image and the AFTER image are determined.
  • the power spectrum for each echo line (k* line) is determined by equation 1
  • E SH is the average of power spectrum in dB scale in the sub- harmonic band
  • P aV g(/) is the average power spectrum
  • f Li is the lower frequency boundary of the sub-harmonic band 272
  • f m is the upper frequency boundary of the sub-harmonic band.
  • the average power spectrum for the fundamental band 274 is determined by equation 4 wherein E F is the average of power spectrum in dB scale in the fundamental band,
  • Pavg(/) is the average power spectrum
  • f L2 is the lower frequency boundary of the fundamental band
  • f H1 is the upper frequency boundary of the fundamental band
  • the average power spectrum for the harmonic band 276 is determined by equation 5 wherein E H is the average of power spectrum in dB scale in the harmonic band, P a v g (/) is the average power spectrum, / i3 is the lower frequency boundary of the harmonic band 276 and f Hi is the upper frequency boundary of the harmonic band. [0071]
  • the average power spectrums (ES H , EF, and EH) are determined for each of the BEFORE image and the AFTER image. The differences in each of the average power spectrums (E SH , EF, and E H ) for each frequency band are then determined as represented in equations 6-8.
  • M 511 E S11 (T x ) -E w (T 0 ) (6)
  • ⁇ E SH , ⁇ E F , and ⁇ E H is then determined, as represented by block 444. It is this energy difference (increase) that corresponds to the value of the tissue change and which is converted to a corresponding visual indicator in block 424 in Fig. 4.
  • the tissue change monitoring is applied to decision making during a HIFU Treatment. These decisions may be made by a surgeon based on the visual indications of the tissue change provided on the display 112 of HEFU System 100. In one embodiment, these decisions are made in the software 109 of HIFU System 100.
  • a BEFORE image is acquired for a given treatment site, as represented by block 500.
  • HIFU Therapy is applied to the treatment site, as represented by block 502.
  • a pause of about 0.5 seconds is inserted after the application of HIFU Therapy to the treatment site.
  • An AFTER image is acquired for the treatment site, as represented by block 504.
  • the tissue change parameter value is determined for one or more regions of interest, as represented by block 506.
  • the tissue change parameter value is compared to a threshold tissue change value, as represented by block 508.
  • tissue change parameter value satisfies the threshold tissue change value
  • the tissue change parameter value is mapped to a visual indication which is displayed on the display of HIFU System 100, as represented by block 510.
  • the transducer is then moved to the next treatment location in a treatment plan and the process is repeated for the new treatment site, as represented by block 512.
  • a decision is made whether to perform an extra exposure at the treatment site, as represented by block 514.
  • the operator of HIFU System 100 determines whether to perform an additional exposure or not.
  • the HIFU System 100 determines whether to perform an additional exposure based on the level of detected tissue change and/or the physician's judgement. If an additional exposure is to be performed, the parameters of the exposure are determined as represented by block 516.
  • the total acoustic power (TAP) and/or HIFU on time (length of HIFU Therapy) are adjusted.
  • the tissue change parameter value from a previous treatment site is used to determine the HIFU exposure variables for a current treatment site.
  • the tissue change parameter value may correspond to a focal zone region of interest.
  • the tissue change parameters value may correspond to a pre-focal zone region of interest.
  • both a tissue change parameter value for a focal zone region of interest and a tissue change parameter value for pre-focal zone region of interest are monitored to determine the variable for a current treatment site.
  • the tissue change parameter value(s) from a previous treatment site adjacent a current treatment site is determined, as represented by block 530.
  • the tissue change parameter value(s) is compared to a tissue change threshold to determine if the tissue change parameter values are acceptable, as represented by block 532.
  • the tissue change parameter value is checked to see if it is at or above the threshold value. If the tissue change value is low, the total acoustic power and/or the duration of the HIFU exposure for the current treatment site may be increased.
  • the tissue change parameter value is checked to see if it is below a threshold value. If the tissue change value is above the threshold amount, microbubbles may have formed in the pre-focal regions. These microbubbles attenuate the HIFU Therapy that is to be delivered to the treatment site.
  • the tissue change value is above the threshold amount, then the total acoustic power for the current treatment site may be reduced and/or the amount of off time before the commencement of the treatment of the current treatment site is increased.
  • the tissue change parameter value(s) being monitored satisfy their respective criteria, then the same total acoustic power and HIFU exposure time used in the adjacent treatment site are used for the current treatment site, as represented by block 534. Treatment at the current treatment site is then commenced, as represented by block 536. If one or more of the tissue change parameter value(s) being monitored do not satisfy their respective criteria, then adjustments are made to the treatment variables for the current treatment site, as represented by block 538. In one embodiment, these adjustments are made by a manual adjustment of the operator of HIFU System 100. In one embodiment, these adjustments are made by KLFU System 100.
  • a current treatment site may be skipped for direct
  • HIFU Therapy due to the fact that it has already been treated indirectly by the HIFU Therapy applied to other (adjacent) treatment sites.
  • a tissue change may have occurred at the current treatment site due to the treatment of proximate treatment sites.
  • HIFU induced tissue change areas grow toward the surface of the transducer if the total acoustic power (TAP) is high and HLFU on time is long enough. For example, when a HIFU Treatment is running with a 40 millimeter focal length transducer, the tissue changes will start to occur at a depth of about 40 millimeters. As the HIFU on time continues, the tissue change area grows toward to the surface of the transducer and may enter the pre-focal zone.
  • TAP total acoustic power
  • TCM readings will be positive when the tissue within the pre-focal region is heated and tissue change has occurred. Skipping the direct treatment of such regions will reduce overall treatment time.
  • a location of the current treatment site is determined, as represented by block 550.
  • the BEFORE and AFTER images for the adjacent treatment sites are reviewed to determine the tissue change parameter value for the current treatment site, as represented by block 552.
  • the tissue change parameter value for the current treatment site is then compared to a threshold value to determine if a sufficient tissue change has occurred due to the indirect treatment of the current treatment site, as represented by block 554. If a sufficient tissue change has occurred then the current treatment site may be skipped, as represented by block 556. If a sufficient tissue change has not occurred due to the indirect treatment of the current treatment site, the current treatment site is treated with HIFU Therapy, as represented by block 558.
  • the BEFORE image for this site is taken directly before treatment.
  • the BEFORE image for this site is the BEFORE image used for an adjacent treatment site.
  • a statistical report of the tissue change parameter values for all treatment sites treated is provided on the display of HLFU System 100.
  • a statistical report 560 is shown and is shown in more detail in Fig. 16.
  • Report 560 indicates the tissue change parameter value for the last treatment site 562, and the number of sites treated 564.
  • a summary 566 of the classification of the tissue change parameter values for each treatment site is also provided. Summary 566 includes the number of sites for which the signal to noise ratio was not sufficient for tissue change monitoring (gray 568), the number of sites for which tissue change was not detected (green 570), the number of sites for which tissue change was detected (yellow 572), and the number of sites for which a large tissue change was detected (orange 574).
  • An operator of HIFU System 100 may determine the success of the HIFU Treatment based on the percentages of sites in the yellow and orange categories. In one embodiment, the HIFU Treatment is likely successful if at least about 90 percent of the sites are in the yellow and orange categories.
  • the monitoring of a tissue change parameter for each treatment site provides feedback to an operator of changes to the tissue which might not be visible as echogenic changes via conventional ultrasound B-mode (2D brightness/echo) images.
  • HIFU parameters such as HIFU on time, HIFU off time, and total acoustic power
  • an operator may modify the treatment of upcoming treatment sites. In one embodiment, this modification may be made automatically by the software of HIFU System 100.
  • the tissue change monitoring also provides an operator with a snapshot of sites that did not exhibit a sufficient amount of tissue change and, providing the possibility for the operator to revisit those sites to provide further HIFU exposure.
  • Tissue change monitoring also provides feedback of the success of the
  • HIFU Treatment during treatment as opposed to traditional method of determining success, such as PSA nadir which make take weeks or months to know if the treatment was successful.
  • the tissue change monitoring examines a two dimensional region of interest to determine the degree of tissue change. Because tissue has non-uniform acoustic properties throughout the treatment region the tissue changes induced by HIFU may also have non-uniform formation. The two dimensional region of interest may capture much more information about the tissue change in the spatial domain than a single one-dimensional RF A-line. This will then provide a more accurate representation of the level of tissue change.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Surgical Instruments (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

L'invention concerne un procédé et un appareil pour déterminer la survenue de changement tissulaire dû à une exposition à une thérapie HIFU.
PCT/US2008/010605 2007-09-11 2008-09-11 Système et procédé pour suivre un changement tissulaire pendant un traitement hifu Ceased WO2009035627A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2699408A CA2699408C (fr) 2007-09-11 2008-09-11 Systeme et procede pour suivre un changement tissulaire pendant un traitement hifu
ES08830580T ES2424874T3 (es) 2007-09-11 2008-09-11 Sistema de seguimiento de un cambio de tejido durante un tratamiento HIFU
EP08830580.0A EP2207596B1 (fr) 2007-09-11 2008-09-11 Systeme pour suivre un changement tissulaire pendant un traitement hifu
JP2010524860A JP5462167B2 (ja) 2007-09-11 2008-09-11 Ｈｉｆｕ治療中の組織変化モニタリングのためのシステム及び方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/853,191 US8235902B2 (en) 2007-09-11 2007-09-11 System and method for tissue change monitoring during HIFU treatment
US11/853,191 2007-09-11

Publications (2)

Publication Number Publication Date
WO2009035627A2 true WO2009035627A2 (fr) 2009-03-19
WO2009035627A3 WO2009035627A3 (fr) 2009-07-02

Family

ID=40432636

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/010605 Ceased WO2009035627A2 (fr) 2007-09-11 2008-09-11 Système et procédé pour suivre un changement tissulaire pendant un traitement hifu

Country Status (6)

Country Link
US (1) US8235902B2 (fr)
EP (1) EP2207596B1 (fr)
JP (1) JP5462167B2 (fr)
CA (1) CA2699408C (fr)
ES (1) ES2424874T3 (fr)
WO (1) WO2009035627A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021050390A1 (fr) * 2019-09-11 2021-03-18 General Electric Company Administration de neuromodulation thérapeutique
US11786211B2 (en) 2018-09-14 2023-10-17 Olympus Corporation Ultrasound imaging apparatus, method of operating ultrasound imaging apparatus, computer-readable recording medium, and ultrasound imaging system

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6050943A (en) 1997-10-14 2000-04-18 Guided Therapy Systems, Inc. Imaging, therapy, and temperature monitoring ultrasonic system
US7914453B2 (en) 2000-12-28 2011-03-29 Ardent Sound, Inc. Visual imaging system for ultrasonic probe
US7393325B2 (en) 2004-09-16 2008-07-01 Guided Therapy Systems, L.L.C. Method and system for ultrasound treatment with a multi-directional transducer
US9011336B2 (en) * 2004-09-16 2015-04-21 Guided Therapy Systems, Llc Method and system for combined energy therapy profile
US7824348B2 (en) 2004-09-16 2010-11-02 Guided Therapy Systems, L.L.C. System and method for variable depth ultrasound treatment
US8444562B2 (en) 2004-10-06 2013-05-21 Guided Therapy Systems, Llc System and method for treating muscle, tendon, ligament and cartilage tissue
US8535228B2 (en) 2004-10-06 2013-09-17 Guided Therapy Systems, Llc Method and system for noninvasive face lifts and deep tissue tightening
US10864385B2 (en) 2004-09-24 2020-12-15 Guided Therapy Systems, Llc Rejuvenating skin by heating tissue for cosmetic treatment of the face and body
US11883688B2 (en) 2004-10-06 2024-01-30 Guided Therapy Systems, Llc Energy based fat reduction
EP1879502A2 (fr) 2004-10-06 2008-01-23 Guided Therapy Systems, L.L.C. Methode et systeme de chirurgie esthetique non invasif
US11235179B2 (en) 2004-10-06 2022-02-01 Guided Therapy Systems, Llc Energy based skin gland treatment
US8133180B2 (en) 2004-10-06 2012-03-13 Guided Therapy Systems, L.L.C. Method and system for treating cellulite
US9694212B2 (en) 2004-10-06 2017-07-04 Guided Therapy Systems, Llc Method and system for ultrasound treatment of skin
KR20130080477A (ko) 2004-10-06 2013-07-12 가이디드 테라피 시스템스, 엘.엘.씨. 초음파 치료 시스템
US20060111744A1 (en) 2004-10-13 2006-05-25 Guided Therapy Systems, L.L.C. Method and system for treatment of sweat glands
US9827449B2 (en) 2004-10-06 2017-11-28 Guided Therapy Systems, L.L.C. Systems for treating skin laxity
US8690779B2 (en) 2004-10-06 2014-04-08 Guided Therapy Systems, Llc Noninvasive aesthetic treatment for tightening tissue
US7758524B2 (en) 2004-10-06 2010-07-20 Guided Therapy Systems, L.L.C. Method and system for ultra-high frequency ultrasound treatment
US11724133B2 (en) 2004-10-07 2023-08-15 Guided Therapy Systems, Llc Ultrasound probe for treatment of skin
US11207548B2 (en) 2004-10-07 2021-12-28 Guided Therapy Systems, L.L.C. Ultrasound probe for treating skin laxity
EP1875327A2 (fr) 2005-04-25 2008-01-09 Guided Therapy Systems, L.L.C. Procede et systeme pour ameliorer la securite de peripherique d'ordinateur
KR100936456B1 (ko) 2006-12-07 2010-01-13 주식회사 메디슨 초음파 시스템
US10456111B2 (en) 2006-12-07 2019-10-29 Samsung Medison Co., Ltd. Ultrasound system and signal processing unit configured for time gain and lateral gain compensation
ES2699477T3 (es) 2007-05-07 2019-02-11 Guided Therapy Systems Llc Métodos y sistemas para acoplar y enfocar energía acústica usando un miembro acoplador
US20150174388A1 (en) 2007-05-07 2015-06-25 Guided Therapy Systems, Llc Methods and Systems for Ultrasound Assisted Delivery of a Medicant to Tissue
EP3181183A1 (fr) 2007-05-07 2017-06-21 Guided Therapy Systems, L.L.C. Procédé et système de régulation de la médication à l'aide de l'énergie acoustique
SI2282675T1 (sl) 2008-06-06 2016-07-29 Ulthera, Inc. Sistem za kozmetični tretma in slikanje
US12102473B2 (en) 2008-06-06 2024-10-01 Ulthera, Inc. Systems for ultrasound treatment
US20090326372A1 (en) * 2008-06-30 2009-12-31 Darlington Gregory Compound Imaging with HIFU Transducer and Use of Pseudo 3D Imaging
US9248318B2 (en) 2008-08-06 2016-02-02 Mirabilis Medica Inc. Optimization and feedback control of HIFU power deposition through the analysis of detected signal characteristics
US9050449B2 (en) * 2008-10-03 2015-06-09 Mirabilis Medica, Inc. System for treating a volume of tissue with high intensity focused ultrasound
WO2010040140A2 (fr) * 2008-10-03 2010-04-08 Mirabilis Mdedica, Inc. Méthode et appareil permettant de traiter des tissus avec des ufhi
CA2748362A1 (fr) 2008-12-24 2010-07-01 Michael H. Slayton Procedes et systemes pour reduire les graisses et/ou traiter la cellulite
JP4997344B2 (ja) * 2009-10-28 2012-08-08 オリンパスメディカルシステムズ株式会社 医療用デバイスの出力制御装置
US8715186B2 (en) 2009-11-24 2014-05-06 Guided Therapy Systems, Llc Methods and systems for generating thermal bubbles for improved ultrasound imaging and therapy
US8568319B1 (en) * 2010-02-11 2013-10-29 Mitchell Kaplan Ultrasound imaging system apparatus and method with ADC saturation monitor
WO2011156624A2 (fr) 2010-06-09 2011-12-15 Regents Of The University Of Minnesota Système de transducteur ultrasonore bimode (dmut) et procédé de commande de l'administration d'une thérapie par ultrasons
JP5759540B2 (ja) * 2010-06-24 2015-08-05 コーニンクレッカ フィリップス エヌ ヴェ 多次元でのｈｉｆｕ治療の実時間モニタリング及び制御
US9504446B2 (en) 2010-08-02 2016-11-29 Guided Therapy Systems, Llc Systems and methods for coupling an ultrasound source to tissue
EP2600937B8 (fr) * 2010-08-02 2024-03-06 Guided Therapy Systems, L.L.C. Systèmes de traitement de lésions aiguës et/ou chroniques dans des tissus mous
US11309081B2 (en) 2010-10-13 2022-04-19 Gholam A. Peyman Telemedicine system with dynamic imaging
US10456209B2 (en) * 2010-10-13 2019-10-29 Gholam A. Peyman Remote laser treatment system with dynamic imaging
US8857438B2 (en) 2010-11-08 2014-10-14 Ulthera, Inc. Devices and methods for acoustic shielding
CN102078818B (zh) * 2010-12-27 2015-04-08 中南民族大学 以sba-16分子筛为载体的催化剂及其制法和应用
US8951266B2 (en) * 2011-01-07 2015-02-10 Restoration Robotics, Inc. Methods and systems for modifying a parameter of an automated procedure
WO2012142455A2 (fr) 2011-04-14 2012-10-18 Regents Of The University Of Minnesota Caractérisation vasculaire utilisant l'imagerie ultrasonore
WO2013009784A2 (fr) 2011-07-10 2013-01-17 Guided Therapy Systems, Llc Système et procédé pour accélérer la cicatrisation d'un matériau implanté et/ou d'un tissu natif
KR20190080967A (ko) 2011-07-11 2019-07-08 가이디드 테라피 시스템스, 엘.엘.씨. 조직에 초음파원을 연결하는 시스템 및 방법
EP2768396A2 (fr) 2011-10-17 2014-08-27 Butterfly Network Inc. Imagerie transmissive et appareils et procédés associés
US9263663B2 (en) 2012-04-13 2016-02-16 Ardent Sound, Inc. Method of making thick film transducer arrays
US9510802B2 (en) 2012-09-21 2016-12-06 Guided Therapy Systems, Llc Reflective ultrasound technology for dermatological treatments
US10025272B2 (en) 2013-01-25 2018-07-17 General Electric Company Ultrasonic holography imaging system and method
CN113648552B (zh) 2013-03-08 2025-03-28 奥赛拉公司 用于多焦点超声治疗的装置和方法
US10561862B2 (en) 2013-03-15 2020-02-18 Guided Therapy Systems, Llc Ultrasound treatment device and methods of use
US9667889B2 (en) 2013-04-03 2017-05-30 Butterfly Network, Inc. Portable electronic devices with integrated imaging capabilities
US10035009B2 (en) 2013-04-15 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treating pancreatic cancer
US11116474B2 (en) * 2013-07-23 2021-09-14 Regents Of The University Of Minnesota Ultrasound image formation and/or reconstruction using multiple frequency waveforms
US9639056B2 (en) * 2013-09-17 2017-05-02 General Electric Company Acoustical holography with multi-level square wave excitation signals
CA2944707C (fr) 2014-04-18 2023-01-24 Ulthera, Inc. Traitement par ultrasons emis par un transducteur a bandes
US10123782B2 (en) 2014-07-07 2018-11-13 The Board Of Trustees Of The Leland Stanford Junior University Integrated system for ultrasound imaging and therapy using per-pixel switches
US9974983B2 (en) 2015-11-12 2018-05-22 SonaCare Medical, LLC Tissue stabilization for therapeutic ultrasound
US11224895B2 (en) 2016-01-18 2022-01-18 Ulthera, Inc. Compact ultrasound device having annular ultrasound array peripherally electrically connected to flexible printed circuit board and method of assembly thereof
PL3981466T3 (pl) 2016-08-16 2023-11-20 Ulthera, Inc. Układy i sposoby dla ultradźwiękowych zabiegów kosmetycznych na skórze
US10589129B2 (en) * 2016-09-14 2020-03-17 Insightec, Ltd. Therapeutic ultrasound with reduced interference from microbubbles
US10300308B2 (en) 2016-09-23 2019-05-28 SonaCare Medical, LLC System, apparatus and method for high-intensity focused ultrasound (HIFU) and/or ultrasound delivery while protecting critical structures
US11458337B2 (en) 2017-11-28 2022-10-04 Regents Of The University Of Minnesota Adaptive refocusing of ultrasound transducer arrays using image data
TWI797235B (zh) 2018-01-26 2023-04-01 美商奧賽拉公司 用於多個維度中的同時多聚焦超音治療的系統和方法
US11944849B2 (en) 2018-02-20 2024-04-02 Ulthera, Inc. Systems and methods for combined cosmetic treatment of cellulite with ultrasound
US11596812B2 (en) 2018-04-06 2023-03-07 Regents Of The University Of Minnesota Wearable transcranial dual-mode ultrasound transducers for neuromodulation
US11260249B2 (en) 2018-07-19 2022-03-01 Sonablate Corp. System, apparatus and method for high intensity focused ultrasound and tissue healing activation
CA3129817A1 (fr) * 2019-02-12 2020-08-20 The Board Of Trustees Of The Leland Stanford Junior University Systemes et procedes pour des ultrasons focalises de haute intensite
CN114126494A (zh) 2019-07-15 2022-03-01 奥赛拉公司 用于利用多维的超声多焦点剪切波的成像来测量弹性的系统和方法
CN113117261B (zh) * 2019-12-30 2023-06-02 重庆融海超声医学工程研究中心有限公司 用于检测空化效应的装置及超声治疗设备

Family Cites Families (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2252580B1 (fr) * 1973-11-22 1980-02-22 Realisations Ultrasoniques Sa
FR2252581B1 (fr) * 1973-11-26 1978-01-06 Realisations Ultrasoniques Sa
CA1050654A (fr) * 1974-04-25 1979-03-13 Varian Associates Dispositif et methode de restitution d'images par ultra-sons
FR2269074B1 (fr) 1974-04-29 1976-10-15 Realisations Ultrasoniques Sa
US4183249A (en) * 1975-03-07 1980-01-15 Varian Associates, Inc. Lens system for acoustical imaging
US4005382A (en) * 1975-08-07 1977-01-25 Varian Associates Signal processor for ultrasonic imaging
US4207901A (en) * 1976-03-11 1980-06-17 New York Institute Of Technology Ultrasound reflector
US4084582A (en) * 1976-03-11 1978-04-18 New York Institute Of Technology Ultrasonic imaging system
US4413630B1 (en) 1976-04-05 1994-04-05 Diasonics Delaware Inc Sector scanner display and recording system for ultrasonic diagnosis
IL49825A0 (en) * 1976-04-05 1976-08-31 Varian Associates Display and recording system for ultrasonic diagnosis
DE2713087A1 (de) * 1976-04-05 1977-10-13 Varian Associates Verfahren zur verbesserung der aufloesung von ultraschallbildern und vorrichtung zur durchfuehrung des verfahrens
FR2352281A1 (fr) 1976-05-21 1977-12-16 Cgr Ultrasonic Procede et dispositif permettant de determiner dans une ebauche tubulaire des troncons de volume rigoureusement predetermine, et application a la decoupe de troncons de poids constant
FR2353270A1 (fr) * 1976-06-03 1977-12-30 Cgr Ultrasonic Appareil d'echographie destine au diagnostic medical, utilisant une sonde a elements multiples
US4209706A (en) * 1976-11-26 1980-06-24 Varian Associates, Inc. Fluoroscopic apparatus mounting fixture
FR2376419A1 (fr) 1977-01-04 1978-07-28 Cgr Ultrasonic Dispositif de visualisation en temps reel pour appareil d'echographie ultrasonore, utilisant un milieu d'interaction acousto-optique
US4317370A (en) * 1977-06-13 1982-03-02 New York Institute Of Technology Ultrasound imaging system
US4227417A (en) 1977-06-13 1980-10-14 New York Institute Of Technology Dynamic focusing apparatus and method
FR2410276A1 (fr) * 1977-11-23 1979-06-22 Cgr Ultrasonic Appareil d'examen echographique a miroir oscillant destine au diagnostic medical
FR2410287A1 (fr) 1977-11-23 1979-06-22 Cgr Ultrasonic Appareil d'echographie medicale a balayage sectoriel de grande ouverture angulaire
US4248090A (en) * 1978-03-27 1981-02-03 New York Institute Of Technology Apparatus for ultrasonically imaging a body
US4231373A (en) 1978-07-18 1980-11-04 Diasonics Ultrasonic imaging apparatus
US4223560A (en) 1979-01-02 1980-09-23 New York Institute Of Technology Variable delay system
US4257271A (en) * 1979-01-02 1981-03-24 New York Institute Of Technology Selectable delay system
US4241610A (en) 1979-02-05 1980-12-30 Varian Associates, Inc. Ultrasonic imaging system utilizing dynamic and pseudo-dynamic focusing
US4241412A (en) 1979-03-16 1980-12-23 Diasonics, Inc. Polar to cartesian mapping apparatus and method
US4290310A (en) 1979-07-09 1981-09-22 Varian Associates, Inc. Ultrasonic imaging system using digital control
US4327738A (en) * 1979-10-19 1982-05-04 Green Philip S Endoscopic method & apparatus including ultrasonic B-scan imaging
US4341120A (en) * 1979-11-09 1982-07-27 Diasonics Cardio/Imaging, Inc. Ultrasonic volume measuring system
US4325381A (en) * 1979-11-21 1982-04-20 New York Institute Of Technology Ultrasonic scanning head with reduced geometrical distortion
FR2477723A1 (fr) * 1980-03-07 1981-09-11 Cgr Ultrasonic Sonde d'echographie ultrasonore a lentille acoustique et echographe comportant une telle sonde
US4410826A (en) 1980-05-27 1983-10-18 Diasonics, Inc. Ultrasonic imaging apparatus using a coupling fluid mixture of propylene oxide, ethylene oxide derivative and glycerine
US4324258A (en) * 1980-06-24 1982-04-13 Werner Huebscher Ultrasonic doppler flowmeters
US4378596A (en) * 1980-07-25 1983-03-29 Diasonics Cardio/Imaging, Inc. Multi-channel sonic receiver with combined time-gain control and heterodyne inputs
US4418698A (en) 1980-07-29 1983-12-06 Jacques Dory Ultrasonic scanning probe with mechanical sector scanning means
US4449199A (en) * 1980-11-12 1984-05-15 Diasonics Cardio/Imaging, Inc. Ultrasound scan conversion and memory system
US4407293A (en) 1981-04-24 1983-10-04 Diasonics, Inc. Ultrasound imaging apparatus for providing simultaneous B-scan and Doppler data
EP0068961A3 (fr) * 1981-06-26 1983-02-02 Thomson-Csf Dispositif d'échauffement localisé de tissus biologiques
DE3210919C2 (de) * 1982-03-25 1986-07-10 Dornier System Gmbh, 7990 Friedrichshafen Vorrichtung zum zerkleinern von Konkrementen in Körpern von Lebewesen
US5150712A (en) 1983-12-14 1992-09-29 Edap International, S.A. Apparatus for examining and localizing tumors using ultra sounds, comprising a device for localized hyperthermia treatment
US5143073A (en) * 1983-12-14 1992-09-01 Edap International, S.A. Wave apparatus system
USRE33590E (en) * 1983-12-14 1991-05-21 Edap International, S.A. Method for examining, localizing and treating with ultrasound
FR2556582B1 (fr) 1983-12-14 1986-12-19 Dory Jacques Appareil a impulsions ultrasonores destine a la destruction des calculs
FR2563725B1 (fr) * 1984-05-03 1988-07-15 Dory Jacques Appareil d'examen et de localisation de tumeurs par ultrasons muni d'un dispositif de traitement localise par hyperthermie
US5150711A (en) 1983-12-14 1992-09-29 Edap International, S.A. Ultra-high-speed extracorporeal ultrasound hyperthermia treatment device
US5158070A (en) 1983-12-14 1992-10-27 Edap International, S.A. Method for the localized destruction of soft structures using negative pressure elastic waves
US5143074A (en) 1983-12-14 1992-09-01 Edap International Ultrasonic treatment device using a focussing and oscillating piezoelectric element
US4664121A (en) * 1984-04-13 1987-05-12 Indianapolis Center For Advanced Research Intraoperative scanner
US4620546A (en) 1984-06-30 1986-11-04 Kabushiki Kaisha Toshiba Ultrasound hyperthermia apparatus
US4638436A (en) * 1984-09-24 1987-01-20 Labthermics Technologies, Inc. Temperature control and analysis system for hyperthermia treatment
US5431621A (en) 1984-11-26 1995-07-11 Edap International Process and device of an anatomic anomaly by means of elastic waves, with tracking of the target and automatic triggering of the shootings
FR2584148B1 (fr) * 1985-06-28 1989-05-05 Dory Jacques Generateur d'impulsions elastiques de grande puissance focalisees dans un liquide et obtenues par percussion
FR2587893B1 (fr) * 1985-09-27 1990-03-09 Dory Jacques Procede et dispositif de reperage permettant, au cours d'une lithotripsie, d'apprecier le degre de fragmentation des calculs
US4807633A (en) * 1986-05-21 1989-02-28 Indianapolis Center For Advanced Research Non-invasive tissue thermometry system and method
FR2614722B1 (fr) 1987-04-28 1992-04-17 Dory Jacques Filtre acoustique permettant de supprimer ou d'attenuer les alternances negatives d'une onde elastique et generateur d'ondes elastiques comportant un tel filtre
FR2614747B1 (fr) * 1987-04-28 1989-07-28 Dory Jacques Generateur d'impulsions elastiques ayant une forme d'onde predeterminee desiree et son application au traitement ou au diagnostic medical
FR2619448B1 (fr) * 1987-08-14 1990-01-19 Edap Int Procede et dispositif de caracterisation tissulaire par reflexion d'impulsions ultrasonores a large bande de frequences, transposition du spectre de frequence des echos dans une gamme audible et diagnostic par ecoute
US4917096A (en) * 1987-11-25 1990-04-17 Laboratory Equipment, Corp. Portable ultrasonic probe
CA1338240C (fr) 1988-03-02 1996-04-09 Laboratory Equipment, Corp. Systeme a ultrasons servant a causer lesions
US4955365A (en) 1988-03-02 1990-09-11 Laboratory Equipment, Corp. Localization and therapy system for treatment of spatially oriented focal disease
US4858613A (en) 1988-03-02 1989-08-22 Laboratory Equipment, Corp. Localization and therapy system for treatment of spatially oriented focal disease
US5036855A (en) 1988-03-02 1991-08-06 Laboratory Equipment, Corp. Localization and therapy system for treatment of spatially oriented focal disease
CA1332441C (fr) 1988-03-02 1994-10-11 Francis J. Fry Systeme de localisation et de traitement d'affections localisees en trois dimensions
US4951653A (en) 1988-03-02 1990-08-28 Laboratory Equipment, Corp. Ultrasound brain lesioning system
US5054470A (en) 1988-03-02 1991-10-08 Laboratory Equipment, Corp. Ultrasonic treatment transducer with pressurized acoustic coupling
FR2643252B1 (fr) * 1989-02-21 1991-06-07 Technomed Int Sa Appareil de destruction selective de cellules incluant les tissus mous et les os a l'interieur du corps d'un etre vivant par implosion de bulles de gaz
US5065761A (en) * 1989-07-12 1991-11-19 Diasonics, Inc. Lithotripsy system
US5033456A (en) 1989-07-12 1991-07-23 Diasonic Inc. Acoustical lens assembly for focusing ultrasonic energy
US5134988A (en) 1989-07-12 1992-08-04 Diasonics, Inc. Lens assembly for focusing energy
US4945898A (en) 1989-07-12 1990-08-07 Diasonics, Inc. Power supply
US5149319A (en) 1990-09-11 1992-09-22 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids
DE4005228A1 (de) * 1990-02-20 1991-08-22 Wolf Gmbh Richard Lithotripsie-einrichtung mit einer anlage zur aufbereitung des akustischen koppelmediums
US5215680A (en) * 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
US5117832A (en) * 1990-09-21 1992-06-02 Diasonics, Inc. Curved rectangular/elliptical transducer
US5316000A (en) * 1991-03-05 1994-05-31 Technomed International (Societe Anonyme) Use of at least one composite piezoelectric transducer in the manufacture of an ultrasonic therapy apparatus for applying therapy, in a body zone, in particular to concretions, to tissue, or to bones, of a living being and method of ultrasonic therapy
US5601526A (en) * 1991-12-20 1997-02-11 Technomed Medical Systems Ultrasound therapy apparatus delivering ultrasound waves having thermal and cavitation effects
FR2685872A1 (fr) 1992-01-07 1993-07-09 Edap Int Appareil d'hyperthermie ultrasonore extracorporelle a tres grande puissance et son procede de fonctionnement.
AU3727993A (en) * 1992-02-21 1993-09-13 Diasonics Inc. Ultrasound intracavity system for imaging therapy planning and treatment of focal disease
US5993389A (en) * 1995-05-22 1999-11-30 Ths International, Inc. Devices for providing acoustic hemostasis
US5247935A (en) 1992-03-19 1993-09-28 General Electric Company Magnetic resonance guided focussed ultrasound surgery
US5295484A (en) * 1992-05-19 1994-03-22 Arizona Board Of Regents For And On Behalf Of The University Of Arizona Apparatus and method for intra-cardiac ablation of arrhythmias
US5620479A (en) * 1992-11-13 1997-04-15 The Regents Of The University Of California Method and apparatus for thermal therapy of tumors
US5391197A (en) * 1992-11-13 1995-02-21 Dornier Medical Systems, Inc. Ultrasound thermotherapy probe
DE4238645C1 (de) 1992-11-16 1994-05-05 Siemens Ag Therapeutischer Ultraschall-Applikator für den Urogenitalbereich
DE4240722C2 (de) * 1992-12-03 1996-08-29 Siemens Ag Gerät für die Behandlung von pathologischem Gewebe
US5573497A (en) 1994-11-30 1996-11-12 Technomed Medical Systems And Institut National High-intensity ultrasound therapy method and apparatus with controlled cavitation effect and reduced side lobes
EP0627206B1 (fr) * 1993-03-12 2002-11-20 Kabushiki Kaisha Toshiba Appareil pour traitement medical par ultrasons
DE4310923C2 (de) 1993-04-02 1996-10-31 Siemens Ag Therapieeinrichtung zur Behandlung von pathologischem Gewebe mit einem Katheter
EP0693954B1 (fr) 1993-04-15 1999-07-07 Siemens Aktiengesellschaft Dispositif pour le traitement de maladies du coeur et de vaisseaux proches du coeur
US5840031A (en) 1993-07-01 1998-11-24 Boston Scientific Corporation Catheters for imaging, sensing electrical potentials and ablating tissue
US5630837A (en) * 1993-07-01 1997-05-20 Boston Scientific Corporation Acoustic ablation
JPH07184907A (ja) 1993-12-28 1995-07-25 Toshiba Corp 超音波治療装置
FR2715313B1 (fr) 1994-01-27 1996-05-31 Edap Int Procédé de commande d'un appareil de traitement par hyperthermie à l'aide d'ultrasons.
US5492126A (en) * 1994-05-02 1996-02-20 Focal Surgery Probe for medical imaging and therapy using ultrasound
US5520188A (en) * 1994-11-02 1996-05-28 Focus Surgery Inc. Annular array transducer
US5873902A (en) * 1995-03-31 1999-02-23 Focus Surgery, Inc. Ultrasound intensity determining method and apparatus
US6334846B1 (en) * 1995-03-31 2002-01-01 Kabushiki Kaisha Toshiba Ultrasound therapeutic apparatus
JP3993621B2 (ja) * 1995-03-31 2007-10-17 株式会社東芝 超音波治療装置
US5725482A (en) * 1996-02-09 1998-03-10 Bishop; Richard P. Method for applying high-intensity ultrasonic waves to a target volume within a human or animal body
IT1282689B1 (it) * 1996-02-26 1998-03-31 Circuit Line Spa Dispositivo di conversione della griglia di punti di test di una macchina per il test elettrico di circuiti stampati non montati
US6016452A (en) * 1996-03-19 2000-01-18 Kasevich; Raymond S. Dynamic heating method and radio frequency thermal treatment
US5676692A (en) 1996-03-28 1997-10-14 Indianapolis Center For Advanced Research, Inc. Focussed ultrasound tissue treatment method
WO1997047881A1 (fr) 1996-06-10 1997-12-18 Quantum Sonix Corporation Pompe a transfert du moment cinetique
FR2752461B1 (fr) * 1996-08-14 1998-11-06 Dory Jacques Procede et dispositif pour le traitement de signaux representatifs d'ondes reflechies ou transmises par une structure volumique en vue d'effectuer une exploration et une analyse de cette structure
US6451044B1 (en) 1996-09-20 2002-09-17 Board Of Regents, The University Of Texas System Method and apparatus for heating inflammed tissue
US5769790A (en) * 1996-10-25 1998-06-23 General Electric Company Focused ultrasound surgery system guided by ultrasound imaging
FR2758471B1 (fr) * 1997-01-20 1999-03-26 Rossignol Sa Patin a roulettes en ligne muni d'un frein agissant sur les roulettes
FR2762392B1 (fr) * 1997-04-18 1999-06-11 Jacques Dory Procede et dispositif pour le traitement de signaux representatifs d'ondes reflechies, transmises ou refractees par une structure volumique en vue d'effectuer une exploration et une analyse de cette structure
US5906580A (en) * 1997-05-05 1999-05-25 Creare Inc. Ultrasound system and method of administering ultrasound including a plurality of multi-layer transducer elements
US5879314A (en) * 1997-06-30 1999-03-09 Cybersonics, Inc. Transducer assembly and method for coupling ultrasonic energy to a body for thrombolysis of vascular thrombi
US6093883A (en) 1997-07-15 2000-07-25 Focus Surgery, Inc. Ultrasound intensity determining method and apparatus
US6126619A (en) 1997-09-02 2000-10-03 Transon Llc Multiple transducer assembly and method for coupling ultrasound energy to a body
US6375634B1 (en) * 1997-11-19 2002-04-23 Oncology Innovations, Inc. Apparatus and method to encapsulate, kill and remove malignancies, including selectively increasing absorption of x-rays and increasing free-radical damage to residual tumors targeted by ionizing and non-ionizing radiation therapy
US6575956B1 (en) * 1997-12-31 2003-06-10 Pharmasonics, Inc. Methods and apparatus for uniform transcutaneous therapeutic ultrasound
CN1058905C (zh) * 1998-01-25 2000-11-29 重庆海扶(Hifu)技术有限公司 高强度聚焦超声肿瘤扫描治疗系统
US6685640B1 (en) * 1998-03-30 2004-02-03 Focus Surgery, Inc. Ablation system
US6186951B1 (en) * 1998-05-26 2001-02-13 Riverside Research Institute Ultrasonic systems and methods for fluid perfusion and flow rate measurement
CA2351545C (fr) * 1998-08-19 2010-06-15 University Health Network Mise en oeuvre de l'imagerie par ultrasons haute frequence pour detecter et controler le processus d'apoptose dans les tissus vivants, les tissus ex-vivo et les cultures cellulaires
US6425867B1 (en) * 1998-09-18 2002-07-30 University Of Washington Noise-free real time ultrasonic imaging of a treatment site undergoing high intensity focused ultrasound therapy
US7686763B2 (en) * 1998-09-18 2010-03-30 University Of Washington Use of contrast agents to increase the effectiveness of high intensity focused ultrasound therapy
EP1125121B1 (fr) 1998-10-28 2007-12-12 Covaris, Inc. Appareil et procedes destines au controle d'un traitement par energie sonique
US6508774B1 (en) * 1999-03-09 2003-01-21 Transurgical, Inc. Hifu applications with feedback control
US6666835B2 (en) 1999-05-14 2003-12-23 University Of Washington Self-cooled ultrasonic applicator for medical applications
US20030060736A1 (en) * 1999-05-14 2003-03-27 Martin Roy W. Lens-focused ultrasonic applicator for medical applications
US6217530B1 (en) * 1999-05-14 2001-04-17 University Of Washington Ultrasonic applicator for medical applications
FR2794018B1 (fr) * 1999-05-26 2002-05-24 Technomed Medical Systems Appareil de localisation et de traitement par ultrasons
US6694170B1 (en) * 1999-05-26 2004-02-17 Endocare, Inc. Computer guided surgery for prostatic nerve sparing
US6626899B2 (en) * 1999-06-25 2003-09-30 Nidus Medical, Llc Apparatus and methods for treating tissue
US6307302B1 (en) 1999-07-23 2001-10-23 Measurement Specialities, Inc. Ultrasonic transducer having impedance matching layer
US20040071664A1 (en) * 1999-07-23 2004-04-15 Gendel Limited Delivery of an agent
DE60026313D1 (de) 1999-07-23 2006-04-27 Uutech Ltd Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes
JP2003512103A (ja) 1999-10-18 2003-04-02 フォーカス サージェリー，インコーポレイテッド 分割ビーム変換器
US6656136B1 (en) * 1999-10-25 2003-12-02 Therus Corporation Use of focused ultrasound for vascular sealing
US20030229331A1 (en) 1999-11-05 2003-12-11 Pharmasonics, Inc. Methods and apparatus for uniform transcutaneous therapeutic ultrasound
US6626855B1 (en) * 1999-11-26 2003-09-30 Therus Corpoation Controlled high efficiency lesion formation using high intensity ultrasound
US7374538B2 (en) 2000-04-05 2008-05-20 Duke University Methods, systems, and computer program products for ultrasound measurements using receive mode parallel processing
AU2001257328A1 (en) 2000-04-28 2001-11-12 Focus Surgery, Inc. Ablation system with visualization
AU2001255724A1 (en) 2000-04-29 2001-11-12 Focus Surgery, Inc. Non-invasive tissue characterization
AU2001294598A1 (en) 2000-09-19 2002-04-02 Focus Surgery, Inc. Tissue treatment method and apparatus
US6875176B2 (en) * 2000-11-28 2005-04-05 Aller Physionix Limited Systems and methods for making noninvasive physiological assessments
US7022077B2 (en) * 2000-11-28 2006-04-04 Allez Physionix Ltd. Systems and methods for making noninvasive assessments of cardiac tissue and parameters
US6618620B1 (en) 2000-11-28 2003-09-09 Txsonics Ltd. Apparatus for controlling thermal dosing in an thermal treatment system
US7547283B2 (en) * 2000-11-28 2009-06-16 Physiosonics, Inc. Methods for determining intracranial pressure non-invasively
US7179449B2 (en) 2001-01-30 2007-02-20 Barnes-Jewish Hospital Enhanced ultrasound detection with temperature-dependent contrast agents
US7846096B2 (en) * 2001-05-29 2010-12-07 Ethicon Endo-Surgery, Inc. Method for monitoring of medical treatment using pulse-echo ultrasound
US7135029B2 (en) * 2001-06-29 2006-11-14 Makin Inder Raj S Ultrasonic surgical instrument for intracorporeal sonodynamic therapy
US20040210289A1 (en) 2002-03-04 2004-10-21 Xingwu Wang Novel nanomagnetic particles
JP4551090B2 (ja) * 2002-02-20 2010-09-22 メディシス テクノロジーズ コーポレイション 脂肪組織の超音波処理および画像化
US6716168B2 (en) 2002-04-30 2004-04-06 Siemens Medical Solutions Usa, Inc. Ultrasound drug delivery enhancement and imaging systems and methods
US6846290B2 (en) * 2002-05-14 2005-01-25 Riverside Research Institute Ultrasound method and system
US8376946B2 (en) * 2002-05-16 2013-02-19 Barbara Ann Karamanos Cancer Institute Method and apparatus for combined diagnostic and therapeutic ultrasound system incorporating noninvasive thermometry, ablation control and automation
US20030191396A1 (en) 2003-03-10 2003-10-09 Sanghvi Narendra T Tissue treatment method and apparatus
US20050025797A1 (en) * 2003-04-08 2005-02-03 Xingwu Wang Medical device with low magnetic susceptibility
US20040254419A1 (en) 2003-04-08 2004-12-16 Xingwu Wang Therapeutic assembly
US20050074407A1 (en) * 2003-10-01 2005-04-07 Sonotech, Inc. PVP and PVA as in vivo biocompatible acoustic coupling medium
US20050193451A1 (en) 2003-12-30 2005-09-01 Liposonix, Inc. Articulating arm for medical procedures
US20050154308A1 (en) 2003-12-30 2005-07-14 Liposonix, Inc. Disposable transducer seal
WO2005065371A2 (fr) 2003-12-30 2005-07-21 Liposonix, Inc. Systemes et procedes pour detruire un tissu adipeux
US20050154309A1 (en) 2003-12-30 2005-07-14 Liposonix, Inc. Medical device inline degasser
US7662114B2 (en) 2004-03-02 2010-02-16 Focus Surgery, Inc. Ultrasound phased arrays
US20070219448A1 (en) 2004-05-06 2007-09-20 Focus Surgery, Inc. Method and Apparatus for Selective Treatment of Tissue
CN101090670B (zh) * 2004-08-17 2010-05-26 特赫尼恩研究与发展基金有限公司 超声成像引导的组织破坏系统及方法
WO2006119572A1 (fr) 2005-05-12 2006-11-16 Compumedics Medical Innovation Pty Ltd Diagnostic ultrasons et appareil de traitement
US20090221902A1 (en) 2005-06-02 2009-09-03 Cancercure Technology As Ultrasound Treatment Center
US20070038096A1 (en) * 2005-07-06 2007-02-15 Ralf Seip Method of optimizing an ultrasound transducer
US20070010805A1 (en) * 2005-07-08 2007-01-11 Fedewa Russell J Method and apparatus for the treatment of tissue
US9107798B2 (en) 2006-03-09 2015-08-18 Slender Medical Ltd. Method and system for lipolysis and body contouring
US20080039724A1 (en) * 2006-08-10 2008-02-14 Ralf Seip Ultrasound transducer with improved imaging
US7559905B2 (en) * 2006-09-21 2009-07-14 Focus Surgery, Inc. HIFU probe for treating tissue with in-line degassing of fluid

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11786211B2 (en) 2018-09-14 2023-10-17 Olympus Corporation Ultrasound imaging apparatus, method of operating ultrasound imaging apparatus, computer-readable recording medium, and ultrasound imaging system
WO2021050390A1 (fr) * 2019-09-11 2021-03-18 General Electric Company Administration de neuromodulation thérapeutique
US11602331B2 (en) 2019-09-11 2023-03-14 GE Precision Healthcare LLC Delivery of therapeutic neuromodulation

Also Published As

Publication number Publication date
EP2207596A2 (fr) 2010-07-21
JP2010538740A (ja) 2010-12-16
CA2699408C (fr) 2017-06-20
ES2424874T3 (es) 2013-10-09
WO2009035627A3 (fr) 2009-07-02
EP2207596B1 (fr) 2013-05-15
US8235902B2 (en) 2012-08-07
CA2699408A1 (fr) 2009-03-19
US20090069677A1 (en) 2009-03-12
JP5462167B2 (ja) 2014-04-02

Similar Documents

Publication Publication Date Title
CA2699408C (fr) Systeme et procede pour suivre un changement tissulaire pendant un traitement hifu
US9095695B2 (en) Method and apparatus for treatment of tissue
EP1804670B1 (fr) Endommagement de tissus a guidage par image ultrasonique
US20040030227A1 (en) Method and apparatus for combined diagnostic and therapeutic ultrasound system incorporating noninvasive thermometry, ablation control and automation
EP2684534A1 (fr) Indicateurs de répartition de chaleur et systèmes électro-chirurgicaux les comprenant
KR100932472B1 (ko) 병변조직을 검출하는 초음파 진단 시스템
WO2006106852A1 (fr) Ultrasonographe
JP2007512111A (ja) パルスエコー超音波を用いた医療的な処置の監視方法
WO2001082777A2 (fr) Caracterisation de tissu non invasive
CN112074237B (zh) 用于组织弹性监测和显示的剪切波幅值重建
Van Vledder et al. Intra-operative ultrasound elasticity imaging for monitoring of hepatic tumour thermal ablation
Samimi et al. Monitoring microwave ablation of ex vivo bovine liver using ultrasonic attenuation imaging
US20230405364A1 (en) Ultrasound ablation apparatus and methods of use
US20100069753A1 (en) Method and apparatus for detecting an acoustic obstruction
Han et al. Modeling for quantitative analysis of Nakagami imaging in accurate detection and monitoring of therapeutic lesions by high-intensity focused ultrasound
Kang et al. Real-time ultrasound detection of breast microcalcifications using multifocus twinkling artifact imaging
Seip et al. High-intensity focused ultrasound (HIFU) multiple lesion imaging: comparison of detection algorithms for real-time treatment control
JP2004097474A (ja) 超音波治療装置
Takeuchi et al. Statistical analysis of ultrasonic scattered echoes enables the non-invasive measurement of temperature elevations inside tumor tissue during oncological hyperthermia
Seip et al. Real-time detection of multiple lesions during high intensity focused ultrasound (HIFU) treatments
Vannacci et al. A feasibility study of a novel spectral method using radiofrequency ultrasound data for monitoring laser tissue ablation
Hu et al. A Multimodal Ultrasound-Driven Approach for Automated Tumor Assessment with B-Mode and Multi-Frequency Harmonic Motion Images
KR102670070B1 (ko) 초음파를 이용한 장기 인식 및 초음파 조사시스템
Siebers et al. A classification system for monitoring thermal therapies
Xie et al. Quantitative assessment of thermal lesion stiffness in the liver: Initial ex vivo results

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2010524860

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2699408

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008830580

Country of ref document: EP